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Available online 8 August 2016Background: We have constructed and clinically evaluated a hypoallergenic vaccine for grass pollen allergy,
BM32, which is based on fusion proteins consisting of peptides from the IgE binding sites of the major grass pol-
len allergens fused to preS (preS1+preS2), a domain of the hepatitis B virus (HBV) large envelope proteinwhich
mediates the viral attachment and entry. Aim of this study was the characterization of the HBV-speciﬁc immune
response induced by vaccination of allergic patients with BM32 and the investigation of the vaccines' potential to
protect against infection with HBV.
Methods:Hepatitis B-speciﬁc antibody and T cell responses of patients vaccinated with BM32were studied using
recombinant preS and synthetic overlapping peptides spanning the preS sequence. The speciﬁcities of the anti-
body responses were compared with those of patients with chronic HBV infection. Furthermore, the capacity
of BM32-induced antibodies, to inhibit HBV infection was investigated using HepG2-hNTCP cell-based in vitro
virus neutralization assays.
Findings: IgG antibodies from BM32-vaccinated but not of HBV-infected individuals recognized the sequence
motif implicated in NTCP (sodium-taurocholate co-transporting polypeptide)-receptor interaction of the hepati-
tis B virus and inhibited HBV infection.
Interpretation: Our study demonstrates that the recombinant hypoallergenic grass pollen allergy vaccine BM32
induces hepatitis B-speciﬁc immune responses which protect against hepatitis B virus infection in vitro.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Allergy affects N25% of the population. There are several forms of
intervention tomanage allergic disease. They include allergen avoid-
ance, symptomatic pharmacotherapy, biologics and allergen-speciﬁc
immunotherapy (AIT) but only AIT has disease-modifying and long-
lasting effects (Durham et al., 1999; Larché et al., 2006; Jacobsen et al.,
2007). In order to improve safety, efﬁcacy, convenience and patients'
compliance, hypoallergenic allergy vaccines based on recombinantis B virus core antigen; HBeAg,
rface antigen; NTCP, sodium-
eciﬁc immunotherapy.
of Vienna, Department of
el 18-20, 1090, Vienna, Austria.
alenta).
. This is an open access article underallergen derivatives or synthetic allergen-derived peptides have been
developed and advanced into clinical trials (Valenta, 2002; Jutel and
Akdis, 2014; Marth et al., 2014; Sandrini et al., 2015).
The concept of B cell epitope-based allergy vaccines is based on
recombinant fusion proteins which consist of per se non-allergenic
peptides from the IgE binding sites of major allergens and an allergen
unrelated carrier protein which provides T cell help without activat-
ing pro-inﬂammatory allergen-speciﬁc T cell responses (Focke et al.,
2010; Focke-Tejkl and Valenta, 2012). As candidates for the allergen-
unrelated carrier proteins, viral proteins from rhinovirus and hepati-
tis B virus have been considered (Edlmayr et al., 2011).
We have recently developed such a hypoallergenic vaccine for grass
pollen allergy, BM32, which is based on fusion proteins consisting of
non-allergenic peptides from the IgE binding sites of the four major
grass pollen allergens, Phl p 1, Phl p 2, Phl p 5 and Phl p 6, fused to the
hepatitis B virus-derived surface protein preS (preS1 + preS2),the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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carrier in BM32 because it has been used in HBV vaccines and was
found to be safe (Rendi-Wagner et al., 2006) and preS-fusion pro-
teins could be produced under Good Manufacturing Practice (GMP)
conditions in a quality suitable for clinical trials. Due to lack of con-
formation the allergen-derived peptides are non-allergenic and the
recombinant fusion proteins accordingly lacked IgE reactivity when
tested with sera from grass pollen allergic patients and showed al-
most no induction of basophil activation. Furthermore, upon immu-
nization of animals they induced IgG antibodies which recognized
the natural grass pollen allergens and inhibited allergic patients'
IgE binding and allergen-induced basophil activation (Focke-Tejkl
et al., 2015). Skin testing of grass pollen allergic patients with the re-
combinant preS fusion proteins showed that they did not induce any
relevant immediate or late phase skin reactions (Niederberger et al.,
2015). Vaccination of grass pollen allergic patients with aluminium
hydroxide-adsorbed preS-based fusion proteins revealed that the
BM32 vaccine induced allergen-speciﬁc IgG responses and protected
patients from grass pollen-induced rhinitis as determined in a pollen
challenge chamber (ClinicalTrials.gov number: NCT01445002).
Since it has been shown that preS1-speciﬁc antibodies neutralized
HBV infectivity (Neurath et al., 1986; Glebe et al., 2003) we aimed
to evaluate whether the preS-based grass pollen allergy vaccine
BM32 could also induce HBV-speciﬁc immune responses. Using syn-
thetic peptides spanning the preS-sequence, we mapped preS-
speciﬁc antibody and T cell responses and compared the antibody re-
sponses of BM32-treated subjects with that of individuals, suffering
from chronic HBV infection to explore the possible use of BM32 for
therapeutic vaccination in the latter group. Furthermore we investi-
gated the potential of BM32-induced antibodies to protect against
HBV infection using an in vitro assay based on HBV receptor (sodi-
um-taurocholate co-transporting polypeptide, NTCP) expressing
HepG2 cell lines.2. Material & Methods
2.1. Expression and Puriﬁcation of Recombinant PreS, Synthesis of PreS
Overlapping Peptides, Sequence Alignments
The procedure of the expression and puriﬁcation of a hexahistidine-
tagged recombinant preS protein (preS1 + preS2; genotype A; subtypeFig. 1. Scheme for the construction of the BM32 vaccine. BM32 contains fusion proteins
consisting of the preS domain (i.e., preS1 and preS2) of the large hepatitis B virus envelope
protein (LHB) fusedwith allergen-derived peptides. LHB: Large hepatitis B virus envelope
protein; MHB: Middle hepatitis B virus envelope protein; SHB: Small hepatitis B virus en-
velope protein.adw2, GenBank: AAT28735.1) in Escherichia coli BL21 (DE3, Stratagene,
La Jolla, CA) is described elsewhere (Niespodziana et al., 2011).
Eight peptides at a length of approximately 30 amino acids and an
overlap of 10 amino acids spanning the complete sequence of preS (ge-
notype A, subtype adw2; Supplemental Fig. 1) were synthesized by a
Fmoc (9-ﬂuorenylmethoxycarbonyl) - strategy with HBTU [2-(1H-
Benzotriazol-1-yl)1,1,3,3 tetramethyluronium hexaﬂuorophosphat] ac-
tivation (Liberty Microwave Peptide Synthesis, CEM Corporation, Mat-
thews, NC) as described previously (Focke et al., 2001). Peptides were
puriﬁed by preparative HPLC and their identity was conﬁrmed by
mass spectrometry (Microﬂex MALDI-TOF, Bruker, Billerica, MA).
An alignment of the preS genotype A, serotype adw2 sequence and
peptide sequences thereof with HBV genotypes B–H was performed
with CLUSTAL Ω using reference sequences from the HBV data base
(HBVdb: https://hbvdb.ibcp.fr/HBVdb/HBVdbIndex),(Hayer et al.,
2012).
2.2. Immunization of Rabbits and Mice
Speciﬁc rabbit antibodies against recombinant preS were raised by
immunization of a New Zealand white rabbit with puriﬁed preS
(200 μg per injection) using Freund's complete adjuvant (CFA) for the
ﬁrst and incomplete Freund's adjuvant (IFA) for the second and third in-
jection (Charles River, Kisslegg, Germany). In addition, New Zealand
white rabbits were immunized three times with a mix containing
20 μg (n = 2) or 40 μg (n = 2) of each of the four BM32 components
(BM32–20/BM32–40) using Al(OH)3 as adjuvant (Focke-Tejkl et al.,
2015).
Furthermore, rabbit antibodies speciﬁc for the registered HBV vac-
cine ENGERIX-Bwere obtained by immunizing New Zealandwhite rab-
bits (n= 2) three-times with commercially available ready-to-use pre-
ﬁlled syringes (20 μg HBsAg/ml) at an interval of one month.
With approval of the animal ethics committee, six-week-old BALB/c
mice (Charles River) (six animals/group) were immunized three times
in a four weeks interval subcutaneously with Al(OH)3-adsorbed mixes
containing 10, 20 and 30 μg of each of the BM32 components. Animals
were kept in the animal care unit of the Department of Pathophysiology
and Allergy Research, Medical University of Vienna according to the
local guideline for animal care. Serum sampleswere obtained before im-
munization and approximately fourweeks after the third immunization
and stored at−20 °C until analysis for preS-speciﬁc antibodies (Fig. 2).
2.3. Human Subjects
Serum samples from BM32 immunized subjects were obtained in
the course of two clinical studies. One set of serum samples was obtain-
ed in the course of a safety and dose-ﬁnding phase IIa study
(ClinicalTrials.gov number: NCT01445002) during which patients re-
ceived three injections of Al(OH)3-adsorbed BM32 (i.e., mixes of 10,
20 or 40 μg of each BM32 component or placebo, i.e., Al(OH)3). Sera
were collected before and four weeks after the third immunization
and stored at−20 °C until usage. This study was approved by the Clin-
ical Pharmacology Ethics Committee of the city of Vienna. A second set
of serum samples was obtained in the course of a phase IIb study
(ClinicalTrials.gov number: NCT01538979) during which patients
were treated over a period of two years with seven subcutaneous injec-
tions of Al(OH)3-adsorbed BM32 (mixes of 20 or 40 μg of each BM32
component) or Al(OH)3 as placebo. An overview of the latter study is
provided in Fig. 3. Supplemental Table 1 summarizes the characteristics
of the patients (n=30). This studywas approved by the Ethics commit-
tee of the Medical University of Vienna, Austria (EK2092/2012) and all
procedures were performed in accordance with the Declaration of Hel-
sinki. Informed consent was obtained from all subjects included in the
study.
In addition, serum sampleswere obtained from individuals suffering
from chronic HBV infectionwhichwas diagnosed based on clinical data,
Fig. 2. IgG responses towardspreS and synthetic preS-derived overlapping peptides. Optical density values (y-axes: ODvalues at 405nm) corresponding to IgG levels of rabbits immunized
with (a) preS (n= 1), (b) 20 μg of BM32 (n= 2), (c) 40 μg of BM32 (n= 2) or to IgG1 levels of groups of mice (n= 6) immunized with (d) 10 μg, (e) 20 μg or (f) 30 μg of BM32 prior to
(grey bars) and after (black bars) immunization, towards preS and synthetic preS overlapping peptides P1–P8 (x-axes). Results represent medians ± interquartile ranges from triplicate
determinations.
60 C. Cornelius et al. / EBioMedicine 11 (2016) 58–67liver function testing andHBV serummarkers (Supplemental Table 2) at
the Division of Gastroenterology and Hepatology of theMedical Univer-
sity of Vienna.
All sera analyzed, were screened for serological markers for HBV
(i.e., HBV surface antigen [HBsAg]; antibodies to the HBV surface an-
tigen [anti-HBs] as well as antibodies to the HBV core antigen [anti-
HBc] at the Department of Virology, Medical University of Vienna).
2.4. Assessment of PreS- and PreS Peptide-speciﬁc Humoral Immune
Responses
ELISA plates (Nunc, Maxisorb, Roskilde, Denmark)were coated with
the antigens (recombinant preS, synthetic preS-overlapping peptides:
P1–P8) or human serum albumin (negative control) (Behring, King of
Prussia, PA), blocked and washed as described elsewhere (Gallerano
et al., 2015). Incubation was performed with rabbit sera in a dilution
of 1:10,000 (CFA) or 1:500 (BM32–20/BM32–40), with mouse sera in
a dilution of 1:1000 and with human sera diluted differently for the
isotypes and IgG subclasses. For the detection of human total IgG, sera
were diluted 1:100, for IgA, IgG1, IgG2, IgG3, IgG4 as well as IgM, sera
were diluted 1:20 and for detection of IgE antibodies sera were diluted
1:10.
Rabbit IgG was detected by donkey anti-rabbit horse radish
peroxidase-conjugated IgG antibodies, diluted 1:2,500 (GE Healthcare
Cat# NA934-1 ml RRID:AB_772206). Bound mouse IgG1 was detected
by monoclonal rat anti-mouse IgG1 (BD Biosciences Cat# 553440
RRID:AB_394860) diluted 1:1000, followed by horse radish peroxidase-
conjugated goat anti-rat IgG antibodies (GE Healthcare Cat# NA935
RRID:AB_772207), diluted 1:2,500.
Human IgG was detected by rabbit anti-human IgG Fc-speciﬁc
antibody (Jackson ImmunoResearch Labs Cat# 309-005-008
RRID:AB_2339626) diluted 1:10,000, followed by peroxidase-linked donkey anti-rabbit IgG (GE Healthcare Cat# NA934-1 ml
RRID:AB_772206) at a dilution of 1:2500. Human IgA, IgG sub-
classes IgG1, IgG2 and IgG4 as well as human IgM were detected by
puriﬁed mouse anti-human IgA1/IgA2 (BD Biosciences Cat#
555886 RRID:AB_396198), IgG1 (BD Biosciences Cat# 555868
RRID:AB_396186), IgG2 (BD Biosciences Cat# 555873 RRID:AB_
396189), IgG4 (BD Biosciences Cat# 555878 RRID:AB_396191) and
IgM (BD Biosciences Cat# 555856 RRID:AB_396178) antibodies, di-
luted 1:1000 respectively, followed by peroxidase-linked sheep anti
mouse IgG (GE Healthcare Cat# NA931-1 ml RRID:AB_772210) at a
dilution of 1:2500. Monoclonal anti-human IgG3 (Sigma-Aldrich
Cat# B3523 RRID:AB_258549) was diluted 1:5000. Human IgE was
detected by goat anti-human horse radish peroxidase-conjugated
IgE antibodies (KPL Cat# 074-1004 RRID:AB_2616558).
2.5. Assessment of T Cell Responses
Peripheral blood mononuclear cells (PBMC) were obtained from
heparinized blood samples of patients from the phase IIb study
(NCT01538979) through density gradient centrifugation using Ficoll
(Amersham Biosciences, Uppsala, Sweden). PreS-speciﬁc PBMC prolif-
erationwas determined for BM32-vaccinated subjectswhen blood sam-
ples could be obtained (n= 19) at visits 5, 8, M1 andM2 (Fig. 3) by 3H-
thymidine incorporation (Focke-Tejkl et al., 2014).
For certain BM32-immunized patients (n= 11), CD4 and CD8 T cell
responses could be assessed at visit M2 by carboxyﬂuorescein
succinimidyl ester (CFSE) labelling (Quah et al., 2007).
Fluorescent dye-labeled cells were seeded at 200,000 cells/well in
Ultra culture™ serum-free medium (Lonza, Verviers, Belgium) supple-
mented with 2 mmol/L L-glutamine (Sigma Aldrich, St. Louis, MO),
50 mmol/L β-mercaptoethanol (Sigma Aldrich), and 0.02 mg of genta-
micin per milliliter (Sigma Aldrich), in a total volume of 200 μl in 96
Fig. 3.Overview of the treatment period of the BM32 trial. (a) Subjects received seven injections of placebo or BM32 over two years as depicted in the time line. Visits duringwhich blood
samples were obtained are indicated. (b) IgG responses of subjects vaccinated with BM32 or placebo towards preS and synthetic preS-derived overlapping peptides. Shown are optical
density values (y-axes: OD values, means of triplicate determination) corresponding to IgG levels towards preS and peptides P1–P8 measured in subjects with (red symbols) or
without (black symbols) prior HBV vaccination who had been immunized with BM32 or placebo before (V5) and at different time points after immunization (V8 and V15) (x-axes).
Medians (horizontal bars) and signiﬁcant differences are indicated: *P b 0.05, **P b 0.01, ***P b 0.001.
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Cells were either left unstimulated (negative control) or were stim-
ulated with Dynabeads® Human T-Activator CD3/CD28 (3 μg/well
(Invitrogen, Carlsbad, CA)) as positive control or with preS
(0.15 μg/well), equimolar quantities of preS-overlapping peptides
(0.03 μg/well) or with a mixture of the preS-derived overlapping
peptides containing 0.03 μg/well of each peptide and cultured at37 °C in 5% CO2 for seven days before antibody staining and FACS
analysis was conducted.
For ﬂow cytometry the following reagents were used: PerCP/Cy5.5
anti-human CD3 antibody (Clone HIT3a; BioLegend Cat# 300328
RRID:AB_1575008), Brilliant Violet 421™ anti-human CD4 antibody
(Clone RPA-T4; BioLegend Cat# 300532 RRID:AB_10965645), APC
anti-human CD8a antibody (Clone HIT8a; BioLegend Cat# 300911
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(BioLegend Cat# 400251 RRID:AB_893682), Brilliant Violet 421™
mouse IgG1 (BioLegend Cat# 400158 RRID:AB_11150232), APC mouse
IgG1 (BioLegend Cat# 400119 RRID:AB_326441) and Fixable Viability
Dye eFluor® 780 (eBioscience, San Diego, CA).
Flow Cytometry was performed on a BD FACS Canto II (Becton, Dick-
inson and Company, Franklin Lakes, NJ). Twenty thousand events were
acquired per sample and analysis was performed via FlowJo Software,
Version 10. Lymphocytes were gated according to morphological
criteria on a forward and sideward scatter dot blot, dead cells were ex-
cluded by staining of viability dye and gating was focused on CD3CD4
and CD3CD8-positive T cells. Those cells that proliferated in response
to antigen stimulation were identiﬁed by their reduction in CFSE ﬂuo-
rescence intensity. Results represent means of triplicate cultures and
median percentages stimulation of CD3+CD4+ and CD3+CD8+ above
background are shown for the different antigens and the analyzed
patients.2.6. Hepatitis B Virus Neutralization Assays
The HBV inoculum for infection was prepared from supernatants of
HepAd38 cells using a heparin column (GE Healthcare) to isolate viral
particles.
HepG2-hNTCP cells (Ni et al., 2014) were seeded at a density of
3 × 105 cells/well in a 24 well plate. At day two after seeding, the in-
fection medium (DMEM, Invitrogen, Carlsbad, CA) was supplement-
ed with 2.5% Dimethyl sulfoxide (DMSO) (Merck, Darmstadt,
Germany) and at day three cells were infected with HBV. For the
neutralization of HBV particles, patients' sera (10 μl) were pre-
incubated with the HBV inoculum (i.e., 5 μl) (6.9 × 107 genome
equivalents/well) for 30 min at 37 °C, followed by co-incubation of
cells with the patient's sera and virus in presence of 4% polyethylene
glycol 8000 (Sigma Aldrich, St. Louis, MO) for 16 h at 37 °C. The HBV-
neutralizing monoclonal antibody Ma18/7 (14 μg/ml), (Glebe et al.,
2003) was used as positive control.
Following inoculation, cells were washed extensively with PBS and
fresh differentiation medium, supplemented with 2.5% DMSO
(Invitrogen, Carlsbad, CA) was added. Additional medium changes
were performed at day three and day ﬁve post infection (p.i.).
Quantiﬁcation of HBV infection was conducted by the measurement
of secreted hepatitis B e antigen (HBeAg) in the supernatant from cells
collected from day ﬁve to seven p.i. HBeAg was determined by ADVIA
Centaur XPT automated chemiluminescence system (Siemens, Munich,
Germany). Samples were considered as positive at a signal above an
index of 1. For the quantiﬁcation of the percentage of inhibition the
given index of a treated sample was divided by the given index of the
untreated sample and normalized to 100%.
The expression of HBV core protein (HBcAg) was detected by im-
munoﬂuorescence at day seven p.i. Cells were washed with PBS prior
to the ﬁxation with 4% paraformaldehyde (Sigma Aldrich, St. Louis,
MO) for 30 min at room temperature (RT). Next, cells were washed
with PBS followed by permeabilization in 0.25% Triton X-100
(AppliChem GmbH, Darmstadt, Germany) in PBS for 30 min at RT.
Subsequently, cells were incubated overnight at 4 °C with the prima-
ry antibody (anti-HBV core, rabbit polyclonal AK; Dako Cat# B0586
RRID:AB_2335704) diluted in 2% w/v BSA, PBS. On the next day,
cells were washed with PBS and incubated with the secondary anti-
body (goat anti rabbit Alexa 488; Molecular Probes Cat# A11008
RRID:AB_143165) and 4′, 6-Diamidin-2-phenylindo/Hoechst 33342
(Roche Applied Science, Penzberg, Germany) in the dark. For the de-
tection of HBcAg-positive cells, the secondary antibody was incubat-
ed for 2 h at RT, protected from light. Cells were examined under an
epiﬂuorescence microscope at 480 nm for Alexa-488-labeled sec-
ondary antibodies (Invitrogen, Carlsbad, CA) and 360 nm for the nu-
clear staining.2.7. Allergen Microarray
The assessment of speciﬁc IgE towards N170 allergen molecules in
sera of HBV-infected individuals was conducted usingmicro-arrayed al-
lergens by chip technology (Lupinek et al., 2014). Levels of allergen-
speciﬁc IgE antibodies were reported in ISAC Standardized Units (ISU)
with a cut-off of 0.3 ISU.
2.8. Statistical Analysis
Statistics were performed using Prism 6.0 software (GraphPad, San
Diego, CA). Statistical signiﬁcances were determined by 2-tailed paired
Student's t-test in case of normal distribution of data and alternatively
by Wilcoxon rank-sum test when population was not assumed to be
distributed normally. In all ﬁgures with multiple n, data are presented
as median (± interquartile ranges). A P value of b0.05 was considered
signiﬁcant.
3. Results
3.1. Immunization With BM32 Induces IgG Antibodies With Speciﬁcity for
Sequential PreS Epitopes
Fig. 2 shows a comparison of the IgG antibody responses towards
preS and synthetic preS-derived peptides induced in rabbits with CFA-
formulated preS or aluminium hydroxide-adsorbed BM32 (Fig. 2b,
c) as well as IgG1 responses of BALB/c mice immunizedwith aluminium
hydroxide-adsorbed BM32 (Fig. 2d–f). Rabbit antibodies induced with
CFA-formulated preS recognized preS as well as each of the preS-
derived peptides except for P7 (Fig. 2a). Both doses of aluminium-
hydroxide adsorbed BM32 (20 and 40 μg) induced preS-speciﬁc IgG an-
tibodies and IgG antibodies directed mainly to the N-terminal peptides
P1, P2, peptide P6 and towards the C-terminal peptide P8 (Fig. 2a). In-
terestingly, the 20 μg dose appeared to induce stronger IgG responses
than the 40 μg dose but the difference was statistically not signiﬁcant.
IgG1 responses of BALB/c mice immunized with three different doses
of BM32 (10, 20, 30 μg) were directed against preS and mainly against
the C-terminal peptide P8 (Fig. 2d–f). No preS or peptide-speciﬁc IgG re-
sponses were detected in rabbits or mice before immunization (Fig. 2,
grey bars).
3.2. PreS-speciﬁc Antibody Responses of BM32 Immunized Subjects Are Not
Inﬂuenced by Already Existing HBV Immunity
Serum samples from grass pollen allergic patients who had received
immunotherapy with the hypoallergenic grass pollen vaccine BM32 or
with placebo were tested for IgG reactivity to preS and synthetic preS
peptides (Fig. 3). These patients (n = 30) had been screened for HBV
serummarkers (HBsAg, anti-HBs and anti-HBc antibodies) before treat-
ment andwere found to be negative for HBsAg and anti-HBc antibodies.
Due to previous vaccination with a conventional HBV vaccine, twenty-
two of the subjects contained anti-HBs antibodies, indicated as red sym-
bols whereas non-HB-vaccinated subjects are shown in black symbols
(Fig. 3). In contrast to placebo-treated patients, we found that each of
the patients who had received immunotherapy with BM32, developed
robust preS-speciﬁc IgG responses when sera were tested after the
third (V8) aswell as after the seventh (V15) injection (Fig. 3). Since con-
ventional HBV vaccines do not contain preS it was not unexpected that
there was no difference regarding the development of preS-speciﬁc an-
tibody responses in subject who had been or were not HBV vaccinated
before. The preS-speciﬁc IgG responses increased signiﬁcantly from
baseline before immunotherapy (i.e., visit 5 versus visit 8) and further
increased signiﬁcantly between visit 8 and visit 15 (i.e., after the sev-
enth injection) (Fig. 3). The preS-speciﬁc IgG responses in these patients
were directed mainly towards the N-terminal peptides P1, P2 and P3
(Supplemental Fig. 1) and again P1- and P2-speciﬁc IgG responses
63C. Cornelius et al. / EBioMedicine 11 (2016) 58–67showed signiﬁcant increases from baseline (visit 5) to visit 8 and from
visit 8 to visit 15 (Fig. 3). We also found increases of IgG responses
against the other preS-derived peptides P4, P5, P6, P7 and P8 in sera
from patients who had received immunotherapy with BM32 but not
in placebo-treated patients (Fig. 3).3.3. PreS-speciﬁc Antibody Responses of BM32 Immunized Subjects Are
Directed Against Neutralizing Epitopes and Differ From Those of Hepatitis
B Virus-infected Individuals
Fig. 4 depicts a comparison of the preS-speciﬁc isotype and IgG sub-
class responses of allergic patients after immunotherapy with BM32 or
placebowith that of chronically HBV-infected individuals. Immunother-
apy with both doses of BM32 induced a robust preS-speciﬁc IgG re-
sponse in each of the treated patients which was signiﬁcantly higher
than the IgG response in HBV-infected individuals (Fig. 4). No relevant
preS-speciﬁc IgA, IgE or IgM responses were detected in sera of BM32-
or placebo treated patients as well as in HBV-infected individuals
(Fig. 4). Moreover, the preS-speciﬁc IgG subclass response differed be-
tween BM32-treated subjects and HBV-infected individuals. BM32-
treated subjects showed a preferential IgG1 and IgG4 subclass response
to preS whereas HBV-infected individuals mounted some IgG1 and
IgG2 responses towards preS (Fig. 4). The preferential IgG1 and IgG4 sub-
class response in BM32-treated patientswhich is indicative of a Th2-like
immune response cannot solely be attributed to the fact that they are al-
lergic as six out of the nineteen HBV-infected individuals showed IgE
sensitizations but lacked preS-speciﬁc IgG4 responses (Supplemental
Table 2, Fig. 4).
We also found striking differences regarding the epitope speciﬁcity
of preS-speciﬁc antibodies in BM32-treated patients versus HBV-
infected individuals (Fig. 5). BM32-immunized patients but not HBV-
infected individuals showed strong IgG responses towards P1, P2 and
P3 (Fig. 5). This ﬁnding is interesting as the region deﬁned by P1 and
P2 corresponds to a motif within preS1 (Supplemental Fig. 1, red box)
that has been described as an essential domain regarding HBV infectiv-
ity (Glebe et al., 2005; Gripon et al., 2005). Moreover, P2 contains a
motif (Supplemental Fig. 1, blue box) which has previously been
shown as an essential domain for inhibition of infection with HBV
(Neurath et al., 1986; Bremer et al., 2011). Furthermore, P7 wasFig. 4. PreS-speciﬁc antibody responses of subjects vaccinatedwith BM32 or placebo and ofHBV
IgG and IgG subclass (IgG1–IgG4) levels speciﬁc for preS of subjects immunized with placebo (
individuals (n = 19) (x-axes). Medians are indicated by horizontal lines, signiﬁcant differencerecognized exclusively by BM32-treated subjects whereas IgG re-
sponses towards P2 and P6 were found in both groups (Fig. 5).
3.4. Characterization of the PreS-speciﬁc T Cell Responses of BM32 Immu-
nized Subjects
The development of preS-speciﬁc T cell responses in patients who
had received immunotherapy with BM32 is depicted in Fig. 6a. We
found a gradually increasing preS-speciﬁc T cell response which was
signiﬁcantly higher at visits V8, M1 and M2 as compared to baseline at
visit 5 (Fig. 6a). Analysis of the epitope speciﬁcity of the preS-speciﬁc
CD4 cell responses by CFSE staining revealed that P1, P2, P5 and P6 in-
duced the strongest CD4 cell proliferation whereas CD4 responses to-
wards P3, P4 and P7 generated intermediate proliferation (Fig. 6b).
Interestingly, the peptides as well as the peptide mix induced stronger
CD4 cell proliferation than the preS protein itself (Fig. 6b). Albeit at
low frequency, preS and preS peptide-speciﬁc CD8 cell responses were
detected, which were mainly directed towards P2, P3, P6 and P8 and
complete preS (Fig. 6b).
3.5. Antibodies Induced by Immunization with BM32 Inhibit Hepatitis B Vi-
rus Infections In Vitro
Next, we investigatedwhether BM32-induced antibodies can inhibit
HBV infection using in vitro virus neutralization assay based on HepG2-
hNTCP cells (Fig. 7). In the ﬁrst type of assay the expression of HBcAg
after infection of cells is detected by speciﬁc immunoﬂuorescence.
Fig. 7a shows that no HBcAg is detected in uninfected cells whereas it
is stained green in infected but untreated cells (Fig. 7a, middle image).
Further on, expression can be prevented by pre-incubation of virus
with the neutralizing monoclonal antibody Ma18/7 (Glebe et al.,
2003) which is directed against the preS1 domain of the large HBV sur-
face protein (Fig. 7a, right image: positive control). Likewise we found
that pre-incubation of HBV with rabbit antibodies induced by the com-
mercial vaccine Engerix-B or with rabbit anti-BM32 (20 μg dose) anti-
bodies inhibited infection of HepG2-hNTCP cells as visualized by a lack
of green HBcAg-staining (Fig. 7b,c). A similar set of experiments was
performed with sera from BM32- or placebo-treated patients and
three representative examples are depicted in Fig. 7d–f. Sera obtained
from a patient before and after immunization with placebo did not-infected individuals. Shown are optical density values (y-axes: ODvalues) of IgA, IgE, IgM,
n = 8), 20 μg (n = 10) or 40 μg of BM32 (n = 12) at visit 15 as well as of HBV-infected
s are indicated: ***P b 0.001.
Fig. 5. IgG responses of subjects vaccinated with BM32 or placebo and of hepatitis B virus-infected individuals speciﬁc for preS peptides. Shown are optical density values (y-axes: OD
values) of IgG levels speciﬁc for preS-derived peptides (P1–P8) of subjects immunized with placebo (n = 8), 20 μg (n = 10) or 40 μg of BM32 (n = 12) at visit 15 as well as of HBV-
infected individuals (n = 19) (x-axes). Medians are indicated by horizontal lines. P1 (aa 2–31); P2 (aa 22–51); P3 (aa 42–71); P4 (aa 62–91); P5 (aa 82–111); P6 (aa 102–131); P7
(aa 122–151); P8 (aa 142–174).
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from a patient after immunization with 20 μg (Fig. 7e) or from a patient
after immunization with 40 μg (Fig. 7f) strongly inhibited infection of
HepG2-hNTCP cells.
In addition to the staining of the HBcAg we used an assay based on
the measurement of secreted hepatitis B e antigen (HBeAg) by
HepG2-hNTCP cells seven days post infection with HBV as another sur-
rogate marker to quantify the inhibition of HBV infection (Fig. 7Fig. 6. PreS- and peptide-speciﬁc T cell responses. (a) PreS-speciﬁc PBMCproliferations (y-axis:
BM32 (n=19) at different time points (x-axis).Medians (horizontal bars) and signiﬁcant diffe
(left panel) and CD8 (right panel) T cells (y-axes) after stimulationwith preS peptides (P1–P8),
(n= 11) at time pointM2. Results aremeans of triplicates in each patient, medians for all teste
P4 (aa 62–91); P5 (aa 82–111); P6 (aa 102–131); P7 (aa 122–151); P8 (aa 142–174).bottom). Supplemental Table 3 provides the mean of the absolute
HbeAg values measured in the supernatant of HBV-infected HepG2-
hNTCP cells showing the reduction of HBeAg secretion upon incubation
of the viral inoculum with the patient sera. We found that sera from
BM32-treated individuals inhibited HBV infection between 50 and 99%
(Fig. 7 bottom). Furthermore, no relevant differencewas found depend-
ing on the dose and number of BM32 injections, as a similar inhibition
was observed for sera from patients who had received three injectionsstimulation index SI) assessed by [3H] thymidine incorporation in subjects immunizedwith
rences are indicated: *P b 0.05, **P b 0.001, ***P b 0.001. (b) Percentages of proliferated CD4
preS or an equimolar peptidemix (x-axes) in blood samples of BM32-immunized subjects
d subjects are denoted by the horizontal lines. P1 (aa 2–31); P2 (aa 22–51); P3 (aa 42–71);
Fig. 7. Inhibition of hepatitis B virus infection of in vitro infected HepG2-hNTCP cell lines (Ni et al., 2014) by BM32-induced antibodies. Intracellular staining of HBV core antigen (HBcAg:
green) in culturedHepG2-hNTCP cells seven days after addition of (a) buffer (uninfected), HBVwithout orwith the neutralizing antibody (Ma 18/7), (b) serum from rabbits before (pre) or
after (post) immunization with Engerix-B or (c) BM32 (20 μg) or sera obtained at visits V5 and V15 from subjects immunized with (d) placebo, (e) 20 μg or (f) 40 μg of BM32. Bottom:
Percentages of the inhibition (HBeAg secretion) of hepatitis B virus infection of cultured HepG2-hNTCP (x-axis) achieved by pre-incubation of virus with, Ma18/7, serum from a placebo-
treated subjectwithout prior HBV vaccination, sera from subjects after three (grey bars) or seven (black bars) immunizationswith BM32 and sera from rabbits immunizedwith Engerix-B
or BM32.
65C. Cornelius et al. / EBioMedicine 11 (2016) 58–67(Fig. 7 bottom, grey bars) as well as for sera from patients who had re-
ceived seven injections (Fig. 7 bottom, black bars). Also, there was no
obvious difference regarding the degree of inhibition between patients
whohad received the 20 μg or 40 μg dose of BM32 (Fig. 7 bottom). In re-
lation with HBcAg expression, no inhibition of secreted HBeAg wasobserved for serum from a placebo-treated patient. Further on, we ob-
served a N90% reduction in secreted HBeAg after the treatment with
the monoclonal antibody Ma 18/7 (Fig. 7 bottom). Rabbit anti-Engerix
and rabbit anti-BM32 antibodies induced a N99% inhibition of HBV in-
fection (Fig. 7 bottom).
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The preS domain of the hepatitis B virus large surface protein has
recently been used as a carrier molecule for the construction of re-
combinant hypoallergenic vaccines for the treatment of allergy to
cat, birch and grass pollen (Niespodziana et al., 2011; Marth et al.,
2013; Focke-Tejkl et al., 2015). In these vaccines, preS serves as a car-
rier protein providing T cell help for the production of allergen-
speciﬁc IgG antibodies which by this technology can be focused to-
wards the IgE binding sites of the allergens (Marth et al., 2013).
The induction of allergen-speciﬁc IgG antibodies directed against the
IgE binding sites on allergens is achieved by fusing per se non-
allergenic peptides from the IgE binding sites to preS in the form of re-
combinant fusion proteins. The grass pollen allergy vaccine BM32 is the
so farmost advanced version of the hypoallergenic B cell epitope-based
vaccines as it has been evaluated not only in vitro and in experimental
animal models (Focke-Tejkl et al., 2015) but also in vivo in allergic pa-
tients (Niederberger et al., 2015) (ClinicalTrials.gov numbers:
NCT01445002, NCT01538979). In fact, its hypoallergenic nature has
been conﬁrmed in vitro by basophil activation testing and in vivo by
skin testing. Furthermore, it has been shown that it induces allergen-
speciﬁc IgG antibodies which inhibit patients' IgE binding to the natural
allergens and allergen-induced effector cell activation. However, no in-
formation has been available about the ability of BM32 to induce preS-
speciﬁc immune responses, the epitope-speciﬁcity of such a response
and the potential of those antibodies to neutralize HBV infection. Our
results show that immunization of animals (i.e., mice, rabbits) as well
as of allergic patients with BM32 induces robust preS-speciﬁc IgG anti-
body responses. There was no difference in the development of preS-
speciﬁc antibody responses in subjects who had previously received
HBV vaccines and/or contained pre-existing HBV-speciﬁc antibody re-
sponses as compared to subjects without pre-existing HBV immune re-
sponses indicating that a pre-existing HBV immunity has no inﬂuence
on the immunogenicity of BM32. Since conventional HBV vaccines do
not contain preS this result was not unexpected. Our peptide epitope
mapping studies showed that the preS-speciﬁc antibody responses are
directed against several sequential epitopes, among them N-terminal
peptides (i.e., P1, P2)which are supposed to contain inhibitory potential
in regard to HBV infection (Neurath et al., 1986; Bremer et al., 2011) In-
terestingly, patients with chronic HBV infections failed to generate IgG
antibodies towards these peptides but recognized different other se-
quential preS epitopes which are so far not found to be involved in pro-
tection against infection. In fact it has been previously reported that
patients with chronic HBV infections contain preS1-speciﬁc non-
protective antibodies (Alberti et al., 1990). In accordance with our re-
sults, another study found that the C-terminal peptides of preS1 in-
duced antibodies but these did not protect (Bremer et al., 2011). A
limitation of our study is that we could not distinguish between so-
called immunotolerant HBeAg-positive HBV carriers with very high vi-
remia and those without HBeAg or high viremia as well as HBV conva-
lescents who reportedly contain preS1-speciﬁc antibodies (Deepen
et al., 1990) but we did not have access to sera from such subjects.
The quality of the IgG antibody response was different between
BM32-immunized subjects (IgG4 = IgG1 N IgG2) as compared to pa-
tients with chronic HBV infections (IgG1 N IgG2). We think that the pre-
dominance of IgG4 responses in the BM32-immunized subjects is not
due to their allergic condition but rather due to features of the BM32
vaccine, as also allergic patients with chronic HBV infections failed to
mount preS-speciﬁc IgG4 responses.
The development of preS-speciﬁc antibody responses in the BM32-
immunized subjects was accompanied by a preS-speciﬁc CD4 T cell re-
sponse which increased continuously in the course of the immuniza-
tion. Several clinical trials have shown that preS-containing HBV
vaccines are effective and even superior to HBV vaccines containing
only the S protein (Madaliński et al., 2004; Rendi-Wagner et al., 2006;
Schumann et al., 2007; Krawczyk et al., 2014; Shouval et al., 2015).This might be attributed to the induction of preS-speciﬁc antibody re-
sponses by these vaccines but the role of anti-preS antibodies was not
analyzed in these studies. It is also possible that the better immunoge-
nicity may have been caused by the conformational epitopes of the
mammalian cell culture derived HBsAg and possibly by T helper epi-
topes from preS (Gerlich, 2015). Furthermore, our study showed that
the preS-containing grass pollen allergy vaccine BM32 induced IgG an-
tibodies against the important epitopes involved in attachment of HBV
to hepatocytes.We therefore investigatedwhether BM32-induced anti-
bodies may protect against HBV-infections. For this purpose, we immu-
nized rabbits with the currently registered HBV vaccine Engerix-B as
recommended by the manufacturer or with three injections of BM32
as it is used in the building-up phase of BM32 allergen-speciﬁc immuno-
therapy. Rabbit antibodies, induced with both types of vaccines
inhibited HBV infection of hepatocytes completely and equally well.
We also found that sera from grass pollen allergic patients immunized
with BM32 but not sera from patients immunized with placebo
inhibited HBV infection of hepatocytes in vitro.
The latter results indicate, that BM32 not only induces grass pollen
allergen-speciﬁc IgG antibodies but also HBV-neutralizing antibodies
and it is therefore tempting to speculate that BM32 may not only have
anti-allergic but also HBV-neutralizing effects. In summary, our study
reveals a so far unknown feature (i.e., potential HBV-neutralizing activ-
ity) of the grass pollen allergy vaccine BM32 and warrants further stud-
ies designed to investigate the usefulness of BM32 also for HBV
vaccination as there is evidence that a considerable proportion of indi-
viduals show poor response to conventional HBV vaccines, lacking preS.Author Contribution
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